Cibc World Market Inc. Makes New $1.67 Million Investment in Amphastar Pharmaceuticals, Inc. $AMPH

Cibc World Market Inc. purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 62,192 shares of the company’s stock, valued at approximately $1,666,000. Cibc World Market Inc. owned approximately 0.14% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership boosted its stake in shares of Amphastar Pharmaceuticals by 382.9% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 392,310 shares of the company’s stock valued at $10,455,000 after purchasing an additional 311,071 shares in the last quarter. Clark Capital Management Group Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at $7,560,000. Algert Global LLC boosted its stake in shares of Amphastar Pharmaceuticals by 216.1% in the 3rd quarter. Algert Global LLC now owns 392,902 shares of the company’s stock valued at $10,471,000 after purchasing an additional 268,612 shares in the last quarter. UBS Group AG boosted its stake in shares of Amphastar Pharmaceuticals by 367.2% in the 3rd quarter. UBS Group AG now owns 312,274 shares of the company’s stock valued at $8,322,000 after purchasing an additional 245,440 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 267.0% in the 3rd quarter. Bridgeway Capital Management LLC now owns 312,337 shares of the company’s stock valued at $8,324,000 after purchasing an additional 227,225 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

AMPH has been the topic of several research reports. Wells Fargo & Company reiterated an “equal weight” rating and set a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Thursday, May 14th. Piper Sandler reiterated a “neutral” rating and set a $21.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th. Barclays reduced their price target on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Wednesday, June 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Reduce” and an average target price of $24.00.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $20.16 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. The stock has a market cap of $888.85 million, a PE ratio of 12.14, a price-to-earnings-growth ratio of 3.81 and a beta of 0.91. The stock has a 50-day moving average of $20.05 and a 200-day moving average of $23.48. Amphastar Pharmaceuticals, Inc. has a one year low of $16.65 and a one year high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The business had revenue of $171.17 million during the quarter, compared to analyst estimates of $173.46 million. As a group, sell-side analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.